Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|October 2, 2024

How Type 2 Inflammation Influences Treatment Choices

Panelists discuss how identifying type 2 inflammation in patients influences treatment decisions by steering clinicians toward targeted therapies, such as biologics or other immunomodulators, that specifically address the underlying inflammatory mechanisms rather than relying solely on symptomatic treatments.

Episodes in this series

This series features 1 KOL.

EP. 1 Navigating the Challenges of Respiratory Diseases

1 KOL is featured in this series.

EP. 2 The Impact of Atopic Dermatitis and Prurigo Nodularis

This series features 1 KOL.

EP. 3 Linking Type 2 Inflammation to Asthma and COPD

This series features 1 KOL.

EP. 4 Impact of Exacerbations in Type 2 Inflammatory Respiratory Diseases

1 KOL is featured in this series.

EP. 5 Type 2 Inflammation: The Link Between AD and PN

1 KOL is featured in this series.

EP. 6 Personalizing Treatment Selection

1 KOL is featured in this series.

EP. 7 Navigating Treatment Challenges in Chronic Skin Conditions

1 KOL is featured in this series.

EP. 8 Role of Biologics in Dermatological Care

This series features 1 KOL.

EP. 9 Biomarkers as Tools in Management of Type 2 Inflammation

This series features 1 KOL.

EP. 10 Strategies to Manage Type 2 Inflammation in Respiratory Diseases

1 KOL is featured in this series.

EP. 11 Addressing Unmet Needs and Emerging Agents

This series features 1 KOL.

EP. 12 Future Directions for Type 2 Inflammation Management

1 KOL is featured in this series.

EP. 13 Type 2 Inflammatory Diseases and Impact on Quality of Life

1 KOL is featured in this series.

EP. 14 Type 2 Inflammation Biomarkers

1 KOL is featured in this series.

EP. 15 How Type 2 Inflammation Influences Treatment Choices

1 KOL is featured in this series.

EP. 16 Complications of Uncontrolled Disease and Management of Comorbidities

1 KOL is featured in this series.

EP. 17 Patient Education and Emerging Therapies

1 KOL is featured in this series.

EP. 18 Unmet Needs and Future Research

In your experience, how does knowing a patient has type 2 inflammation influence the choice in treatment?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Catching DME Patients Before They Fall Off the Radar: Sunir Garg, MD

ByLaura Joszt, MA,Sunir Garg, MD

June 22nd 2026

Navigating the Human Side of Extrapulmonary Neuroendocrine Carcinoma: Patient Burden and Caregiver Support

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 22nd 2026

The 5-Year Horizon: Evolving Paradigms in Ischemic Stroke Management

ByMark Makhinson, PharmD, MBA,Andrew Russman, DO, FAHA, FAAN,Danison Emmerson, MD,David Z. Rose, MD

June 22nd 2026

Closing the Gap: Underrecognition and the Critical Need for Early Diagnosis in Extrapulmonary Neuroendocrine Carcinoma

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 22nd 2026

Anita Kumar, MD, of MSKCC in Basking Ridge, New Jersey, highlighted advances in treatment of transplant-ineligible mantle cell lymphoma, including chemotherapy-free options. | Image: MSKCC

Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains

June 20th 2026

Trending on AJMC

Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently

Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains

Study Finds Flaw in Method for Key Oncology Value-Based Care Model

Defunding Co-Payment Assistance Disrupted nAMD Care

Aficamten Outperforms Metoprolol Across All Phases of Exercise in Obstructive HCM